Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Current Assets (2022 - 2026)

Sagimet Biosciences' Current Assets history spans 5 years, with the latest figure at $107.7 million for Q1 2026.

  • Quarterly Current Assets fell 26.26% to $107.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $107.7 million through Mar 2026, down 26.26% year-over-year, with the annual reading at $116.4 million for FY2025, 23.81% down from the prior year.
  • Current Assets came in at $107.7 million for Q1 2026, down from $116.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $194.5 million in Q1 2024 to a low of $21.4 million in Q2 2023.
  • The 5-year median for Current Assets is $119.5 million (2025), against an average of $118.6 million.
  • Year-over-year, Current Assets soared 680.89% in 2024 and then fell 26.26% in 2026.
  • Sagimet Biosciences' Current Assets stood at $32.8 million in 2022, then surged by 194.72% to $96.6 million in 2023, then skyrocketed by 58.08% to $152.8 million in 2024, then decreased by 23.81% to $116.4 million in 2025, then dropped by 7.46% to $107.7 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Current Assets are $107.7 million (Q1 2026), $116.4 million (Q4 2025), and $119.5 million (Q3 2025).